GeneMind Biosciences Funding: $214M Raised, Series C (2023)
GeneMind Biosciences is based in Shenzhen, China. It has raised $214M in total funding. Latest round: Series C.
GeneMind Biosciences funding overview
GeneMind Biosciences is based in Shenzhen, China. GeneMind Biosciences has raised $214M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series C announced in August 2023. The round record for GeneMind Biosciences runs through 2023; nothing later has been disclosed. Investors on record include Guoxin Investment, Guangzhou Kingmed Diagnostics Group. 2 distinct backers are named across the disclosed rounds.
GeneMind Biosciences at a glance
Total raised
$214M
Latest round
Series C
Latest round date
August 2023
Headquarters
Shenzhen, China
Notable investors
Guoxin Investment, Guangzhou Kingmed Diagnostics Group
Frequently asked about GeneMind Biosciences funding
How much has GeneMind Biosciences raised?
GeneMind Biosciences has raised $214M in total disclosed funding across the rounds on record.
Who has invested in GeneMind Biosciences?
Guoxin Investment, Guangzhou Kingmed Diagnostics Group are named among the investors backing GeneMind Biosciences.
What was the latest GeneMind Biosciences funding round?
The most recent disclosed round is a Series C, announced in August 2023.
Where is GeneMind Biosciences based?
GeneMind Biosciences is based in Shenzhen, China.
When did GeneMind Biosciences last raise?
The last disclosed GeneMind Biosciences round closed in August 2023 at Series C.
Every GeneMind Biosciences figure above comes from filings and announced rounds in the StartupFundraising company database and is revised as new rounds are recorded. The lists below compare companies in Shenzhen at a similar stage.
